| 195 | 0 | 66 |
| 下载次数 | 被引频次 | 阅读次数 |
从“痰毒流注”理论探析进展期胃癌的中医病机演变特征与转移机制。基于痰毒流注理论，认为进展期胃癌呈现正气亏虚、痰毒流注、络损血瘀的病机演变特征。其中，正气亏虚为发病之本，脾肾不足致正气衰微，无力抗邪；痰毒流注为中心环节，痰湿与癌毒胶结，流注他脏；络损血瘀为最终病理环节，痰毒阻滞损伤络脉，痰瘀互结致积。在此基础上，进一步分析进展期胃癌向肝、腹膜、肺、骨、脑、卵巢、淋巴结等多部位转移的经络循行路径及转移机制，为该病的临床治疗与研究提供思路。
Abstract：This article systematically explores the traditional Chinese medicine(TCM) pathogenesis evolution and metastatic mechanisms of advanced gastric cancer from the perspective of "phlegm-toxin flowing infusion". Based on this theory, it is proposed that advanced gastric cancer presents a pathogenesis evolution characterized by healthy qi depletion, phlegm-toxin flowing infusion, and collateral damage with blood stasis. Healthy qi depletion is the root of the disease, in which spleen and kidney insufficiency leads to weakened healthy qi and inability to resist patho‑genic factors. Phlegm-toxin flowing infusion is the core pathogenesis, where phlegm-dampness and cancer toxin inter‑twine and migrate to other organs along with qi movement. Collateral damage with blood stasis constitutes the final pathological stage of metastasis, where phlegm-toxin obstruction damages the collaterals, and congealed qi and blood form accumulations. On this basis, the meridian pathways and metastasis mechanisms of advanced gastric can‑cer spreading to multiple sites such as the liver, peritoneum, lungs, bones, brain, ovary, and lymph nodes are further analyzed, providing references for clinical management and research of this disease.
[1]BRAY F, LAVERSANNE M, SUNG H, et al. Global can‑cer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2024,74(3):229-263.
[2]AJANI JA, D'AMICO TA, BENTREM DJ, et al. Gastric cancer, version 2. 2022, NCCN clinical practice guide‑lines in oncology[J]. J Natl Compr Canc Netw,2022,20(2):167-192.
[3]PARK H, CHO YS, PARK DJ, et al. Conditional relative survival among patients with gastric cancer undergoing sur‑gery:a hospital-based cohort study[J]. J Gastric Cancer,2025,25(4):581-592.
[4]LEONG T, SMITHERS BM, HAUSTERMANS K, et al.TOPGEAR:a randomized, phaseⅢtrial of perioperative ECF chemotherapy with or without preoperative chemoradi‑ation for resectable gastric cancer:interim results from an international, intergroup trial of the AGITG, TROG,EORTC and CCTG[J]. Ann Surg Oncol,2017,24(8):2252-2258.
[5]HAO JL, LI XY, LIU YT, et al. Antibody-drug conju‑gates in gastric cancer:from molecular landscape to clini‑cal strategies[J]. Gastric Cancer,2024,27(5):887-906.
[6]RATTI M, ORLANDI E, TOSCANI I, et al. Emerging therapeutic targets and future directions in advanced gas‑tric cancer:a comprehensive review[J]. Cancers(Basel),2024,16(15):2692.
[7]SATOH T, XU RH, CHUNG HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treat‑ment of HER2-amplified advanced gastric cancer in Asian populations:TyTAN:a randomized, phaseⅢstudy[J].J Clin Oncol,2014,32(19):2039-2049.
[8]BELL HN, ZOU W. Beyond the barrier:unraveling the mechanisms of immunotherapy resistance[J]. Annu Rev Immunol,2024,42(1):521-550.
[9]王文萍，王垂杰.肿瘤转移的“痰毒流注”理论形成基础及实践意义[J].中国中医基础医学杂志，2002,8(5):4-6.
[10]吴以岭.络病病机探析[J].中医杂志，2005,46(4):243-245.
[11]张乙.中医体质与胃癌术后复发转移及生存质量的相关性研究[D].北京：北京中医药大学，2019.
[12]张亚丽，谢建国.浅谈奥沙利铂所致周围神经毒性的中医辨证论治[J].中医临床研究，2019,11(5):144-146.
[13]CHEN J, ZOU L, SUN W, et al. The effects of nutri‑tional support team intervention on postoperative immune function, nutritional statuses, inflammatory responses,clinical outcomes of elderly patients with gastric cancer[J]. BMC Surg,2022,22(1):353.
[14]杨嘉欣.健脾益胃方防治胃癌根治术后复发转移的回顾性队列研究[D].北京：北京中医药大学，2021.
[15]BERA K, KIEPAS A, GODET I, et al. Extracellular fluid viscosity enhances cell migration and cancer dissemination[J]. Nature,611(7935):365-373.
[16]程海波.癌毒病机理论探讨[J].中医杂志，2014,55(20):1711-1715.
[17]王文萍．实用肿瘤转移学[M].沈阳：辽宁科学技术出版社，2002:17.
[18]朱晶，王琦苑，钱蓉，等.消痰散结方联合卡培他滨治疗晚期胃癌临床研究[J].陕西中医，2024,45(2):191-195.
[19]赵颖，陆烨，施俊，等.消痰散结方为基础的中药辨证治疗对中晚期胃癌无进展生存期影响的研究[J].中国中西医结合消化杂志，2017,25(5):332-335,339.
[20]曹丽萍.消痰散结方通过调控LncRNA-ATB抑制胃癌细胞增殖和转移[D].杭州：浙江中医药大学，2022.
[21]余志红，赵颖，魏品康，等.消痰散结方对原位移植胃癌裸鼠生长及血清IL-8、TGF-β的影响[J].中华中医药学刊，2018,36(10):2382-2385.
[22]常中飞，胡秀敏，陈培丰.运用中医理论探讨恶性肿瘤转移新学说：“经络转移学说”[J].中华中医药学刊，2008,26(1):167-169.
[23]常富业，王永炎，高颖，等.络脉概念诠释[J].中医杂志，2005,46(8):566-568.
[24]张凡勇，张娜，方亮.清热解毒化痰汤对晚期胃癌术后痰毒瘀结证患者生活质量的影响[J].世界中西医结合杂志，2018,13(9):1286-1289,1317.
[25]王立玉，陈舲，王芹，等.三棱消瘤合剂联合化疗治疗痰瘀互结型进展期胃癌的临床观察[J].上海中医药杂志，2023,57(4):36-40.
[26]陈婷，陈灵，丁敏.加味半夏厚朴汤联合康艾注射液治疗痰瘀互结型晚期胃癌的临床研究[J].基层医学论坛，2022,26(17):50-52.
[27]RIIHIMAKI M, HEMMINKI A, SUNDQUIST K, et al.Metastatic spread in patients with gastric cancer[J].Oncotarget,2016,7(32):52307-52316.
[28]YU Z, LIANG C, GAO J, et al. Clinicopathologic factors correlated with lymph node metastasis in gastric cancer:a retrospective cohort study involving 5606 patients[J].J Gastrointest Surg,2024,28(8):1242-1249.
[29]QIU MZ, SHI SM, CHEN ZH, et al. Frequency and clinicopathological features of metastasis to liver, lung,bone, and brain from gastric cancer:a SEER-based study[J]. Cancer Med,2018,7(8):3662-3672.
[30]CONDE MONROY D, IBANEZ-PINILLA M, SABOGAL JC, et al. Survival outcomes of hepatectomy in gastric cancer liver metastasis:a systematic review and metaanalysis[J]. J Clin Med,2023,12(2):704.
[31]KIM JH, LEE HH, SEO HS, et al. Stage-specific difference in timing and pattern of initial recurrence after curative surgery for gastric cancer[J]. Surg Oncol,2019,30:81-86. doi:10. 1016/j. suronc. 2019. 05. 023.
[32]RIJKEN A, LURVINK RJ, LUYER MDP, et al. The burden of peritoneal metastases from gastric cancer:a systematic review on the incidence, risk factors and survival[J]. J Clin Med,2021,10(21):4882.
[33]CHEN AH, CHAN WH, LEE YH, et al. Routine chest CT for staging of gastric cancer[J]. Br J Surg,2019,106(9):1197-1203.
[34]麦麦提艾力·图尔荪，张文斌.胃癌肺转移患者118例预后影响因素分析[J].中华肿瘤防治杂志，2019,26(15):1107-1110.
[35]TURKOZ FP, SOLAK M, KILICKAP S, et al. Bone metastasis from gastric cancer:the incidence, clinico‑pathological features, and influence on survival[J]. J Gastric Cancer,2014,14(3):164-172.
[36]ZHANG C, ZHANG X, FENG C, et al. Bone metastasis is a late-onset and unfavorable event in survivors of gastric cancer after radical gastrectomy:results from a clinical observational cohort[J]. Cancer Pathog Ther,2024,2(1):50-57.
[37]ZHU Y, ZHOU M, LI C, et al. Gastric cancer with brain metastasis:from molecular characteristics and treatment[J]. Front Oncol,2024,14:1310325. doi:10.3389/fonc. 2024. 1310325.
[38]ZHANG L, YU Z, ZHANG Y, et al. A nomogram based on clinicopathological characteristics for estimating the risk of brain metastasis from advanced gastric cancer:a multi-center retrospective clinical study[J]. Ther Clin Risk Manag,2024,20:391-404. doi:10. 2147/TCRM.S460647.
[39]FENG Q, PEI W, ZHENG ZX, et al. Clinicopathologic characteristics and prognostic factors of 63 gastric cancer patients with metachronous ovarian metastasis[J]. Cancer Biol Med,2013,10(2):86-91.
[40]ZHANG F, ZHANG X, ZHANG X, et al. Recurrent metastatic patterns and prognosis after radical surgery in patients with alpha-fetoprotein-producing gastric cancer:a retrospective cohort study[J]. Am J Cancer Res,2024,14(5):2124-2140.
[41]SONG K, WU J, XU M, et al. An ensemble learning model to predict lymph node metastasis in early gastric cancer[J]. Sci Rep,2025,15(1):11257.
基本信息:
DOI：10.13288/j.11-2166/r.2026.05.006
中图分类号:R273
引用信息:
[1]闫星羽,王文萍.从“痰毒流注”理论探析进展期胃癌的中医病机演变与转移机制[J].中医杂志,2026,67(05):492-497.DOI:10.13288/j.11-2166/r.2026.05.006.
基金信息:
辽宁省中医药交叉创新团队项目（LNZYYCXTD-JCCX-002）; 2022辽宁省中医大师（辽宁省名中医）传承工作室建设项目（辽中医药综合字[2021]32号）